Filing Flows › Organogenesis Holdings (ORGO) › Q2 2025
Organogenesis Holdings (ORGO) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 7, 2025
Organogenesis Holdings (ORGO) reported revenue of $101M for the second quarter 2025 (Q2 2025), -22% from a year earlier and +17% from the quarter before. Operating margin was -12.5%, net loss $9.4M (9.3% of revenue).
Organogenesis Holdings, Q2 2025: revenue $101M (-22% year over year), operating margin -12.5%, net loss $9.4M, operating cash flow −$32.9M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $101M | +17% | -22% |
| Operating profit | −$12.6M | — | — |
| Net earnings | −$9.4M | — | — |
| Operating cash flow | −$32.9M | — | — |
What changed
Revenue was $101.0M in Q2 2025, down 22% year over year and up 17% from the previous quarter. Product was the largest line at 100% of revenue. Product lost $29.5M year over year (down 23%), 101% of the total change.
Operating costs exceeded revenue by $12.6M, an operating margin of -12.5%. The fastest-growing cost line was Other operating costs (+29%). The quarter ended with a net loss of $9.4M, narrower than the previous quarter's $18.8M loss.
Operating cash flow was −$32.9M. Non-cash charges added back $4.6M of depreciation and amortization and $2.5M of share-based compensation. Working capital and other items used $30.6M. Capital expenditures of $3.6M exceeded it, leaving free cash flow of −$36.5M.
Questions
What was Organogenesis Holdings' revenue in the second quarter 2025?
Organogenesis Holdings (ORGO) reported revenue of $101M for the second quarter 2025 (Q2 2025), -22% from a year earlier and +17% from the quarter before.
Was Organogenesis Holdings profitable in the second quarter 2025?
Operating loss was $12.6M (-12.5% of revenue) and net loss $9.4M.